HSBC downgraded AstraZeneca to 'hold' from 'buy' after a recent trial failure removed the core pillar of its bull case, while the outlook has become tougher. The target price was cut to 13,750p from 16,500p, suggesting limited upside. Overall sentiment is cautious following the downgrade and reduced valuation upside.
HSBC downgraded AstraZeneca to 'hold' from 'buy' after a recent trial failure removed the core pillar of its bull case, while the outlook has become tougher. The target price was cut to 13,750p from 16,500p, suggesting limited upside. Overall sentiment is cautious following the downgrade and reduced valuation upside.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly negative
Sentiment Score
-0.35
Ticker Sentiment
